Last reviewed · How we verify

Ropivacaine and dexamethasone

University of Texas Southwestern Medical Center · Phase 3 active Small molecule

Ropivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while dexamethasone reduces inflammation and prolongs the duration of the anesthetic effect.

Ropivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while dexamethasone reduces inflammation and prolongs the duration of the anesthetic effect. Used for Peripheral nerve blocks and local anesthesia with prolonged duration, Postoperative pain management.

At a glance

Generic nameRopivacaine and dexamethasone
Also known asNoropin and adjuvant, Ropivacaine Hydrochloride Injection, Naeopin
SponsorUniversity of Texas Southwestern Medical Center
Drug classLocal anesthetic with corticosteroid adjuvant
TargetVoltage-gated sodium channels; glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhasePhase 3

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx in nerve cell membranes, preventing depolarization and nerve impulse conduction. Dexamethasone, a corticosteroid, is added to reduce local inflammation and extend the duration of anesthesia by decreasing vascular uptake of the local anesthetic and modulating inflammatory mediators at the injection site.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: